TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Biophytis SA ( (FR:ALBPS) ) has shared an announcement.
Biophytis SA has secured a non-dilutive bond financing line of up to €1 million from Hexagon Capital Fund to support its ongoing operations, particularly the clinical development of its OBA101 program. This financing strengthens the company’s cash position, enabling it to meet its financial needs through the first quarter of 2026. The bonds, issued with a nominal value of €1,000, will mature 24 months after issuance and bear an annual interest rate of 12%. The transaction allows Biophytis to continue focusing on its core development programs without diluting shareholder equity, although converting bonds into shares could slightly impact shareholder ownership percentages.
More about Biophytis SA
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases, including muscular diseases like sarcopenia and metabolic disorders such as obesity. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Its shares are listed on Euronext Growth Paris and the OTC market.
Average Trading Volume: 299,190
Technical Sentiment Signal: Sell
Current Market Cap: €4.57M
Find detailed analytics on ALBPS stock on TipRanks’ Stock Analysis page.